Sax on HIV/AIDS

• Discordant HIV Status and Conception: Potential Use for PrEP   Paul E. Sax, MD, considers the potential benefits of preexposure prophylactic therapy for HIV in serodiscordant couples trying to conceive.
  Medscape HIV/AIDS, May 2012
• New HIV Treatment Guidelines: Who Should Be Treated?   Paul E. Sax, MD, offers his thoughts on just one of the new HHS recommendations -- treating everyone who is infected with HIV.
  Medscape HIV/AIDS, April 2012
• New Drugs for HIV: Reports From CROI 2012   Paul E. Sax, MD, describes studies reported at CROI that focus on promising new drugs for HIV -- what is in progress, what is coming next.
  Medscape HIV/AIDS, March 2012
• News From CROI: Treatment of HIV/HCV Coinfection   Paul E. Sax, MD, describes reports from CROI on HCV and HIV -- all very interesting, some promising.
  Medscape HIV/AIDS, March 2012
• Eliminating Perinatal HIV Infections: Challenges Remain   We know how to prevent HIV in newborns, so why aren't we 100% successful? Paul E. Sax, MD, comments on a new study in the journal Pediatrics.
  Medscape HIV/AIDS, February 2012
• When to Start ART? More Data   Paul E. Sax, MD, describes a new study providing guidance on when to start ART in HIV, based on CD4 cell counts.
  Medscape HIV/AIDS, February 2012
• Highlights From New HIV Guidelines   Paul E. Sax, MD, offers the latest on new guidelines for HIV treatment from both the US and the European AIDS Clinical Society.
  Medscape HIV/AIDS, December 2011
• Treatment of Drug-Resistant HIV: Still Waiting   The options are once again limited for the population of multidrug-resistant patients with HIV.
  Medscape HIV/AIDS, December 2011
• A Review of 4 Regimens for Initial ARV Therapy   One of the 4 tenofovir-containing WHO-recommended regimens for initial ARV therapy has not been well studied. A review at IAS indicates that TDF/3TC/NVP may have high rates of virologic failure and emergent drug resistance. Learn more from Paul E. Sax, MD.
  Medscape HIV/AIDS, August 2011
• Investigational ARVs: What Is on the Horizon?   Paul E. Sax, MD, reports on papers presented at IAS, highlighting new drugs in the pipeline.
  Medscape HIV/AIDS, August 2011
• Early ART Prevents HIV Transmission   Paul E. Sax, MD, attended the IAS meeting where more details were provided on the HPTN 052 study of HIV-serodiscordant couples – the biggest story of the meeting. Learn more here.
  Medscape HIV/AIDS, August 2011
• Big News in HIV: Treatment Clearly Protects Partners   We now have real proof that treatment protects against HIV transmission. Paul E. Sax, MD, offers his perspective.
  Medscape HIV/AIDS, May 2011
• HIV: Should We Treat and When Do We Start?   Paul E. Sax, MD, describes new research that offers insight about when to start antiretroviral therapy.
  Medscape HIV/AIDS, April 2011
• Can We Stop Monitoring CD4 Counts Entirely in HIV?   Paul E. Sax, MD, offers a perspective on CD4 monitoring in HIV that you may find surprising.
  Medscape HIV/AIDS, March 2011
• New Guidelines on HIV PrEP From CDC   Paul E. Sax, MD, provides an overview of the interim guidelines issued by CDC on preexposure prophylaxis (PrEP) for HIV.
  Medscape HIV/AIDS, February 2011
• Top Research in HIV Medicine in 2010   In the second part of his overview of the most important HIV research in 2010, Paul E. Sax, MD, focuses on when to start antiretroviral therapy in different settings and clinical situations.
  Medscape HIV/AIDS, December 2010
• Top Research in HIV Medicine in 2010   In this first installment highlighting the top research in HIV this year, Paul E. Sax, MD, reviews the progress made in prevention and the latest numbers on the epidemic.
  Medscape HIV/AIDS, December 2010
• Preexposure Chemoprophylaxis for HIV Prevention: Landmark Study Results   New research provides the first evidence of efficacy of preexposure chemoprophylaxis in HIV-negative MSM. Paul E. Sax, MD, offers an overview and highlights some of the key questions for clinicians.
  Medscape HIV/AIDS, November 2010
• Can We Ever Cure HIV?   What will come first: a cure for HIV or an effective vaccine? Paul Sax interviews Dan Kuritzkes at ICAAC 2010
  Medscape HIV/AIDS, October 2010
• A Promising New Investigational Integrase Inhibitor for HIV   Exciting new reports at IAS 2010 focused on an investigational once-daily drug, currently referred to as "572." Paul E. Sax, MD, suggests readers stay tuned for more in the coming months.
  Medscape HIV/AIDS, September 2010